Literature DB >> 6196584

Survival after "palliative" cytotoxic chemotherapy for head-and-neck cancer.

P M Stell, R P Morton, I T Campbell, J A Wilson.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1983        PMID： 6196584     DOI： 10.1016/s0140-6736(83)91259-x

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Cisplatinum and bleomycin for advanced or recurrent squamous cell carcinoma of the head and neck: a randomised factorial phase III controlled trial.

Authors:  R P Morton; F Rugman; E B Dorman; P J Stoney; J A Wilson; M McCormick; A Veevers; P M Stell
Journal:  Cancer Chemother Pharmacol       Date:  1985       Impact factor: 3.333

Review 2.  Balancing Safety and Efficacy of Epidermal Growth Factor Receptor Inhibitors in Patients With Squamous Cell Carcinoma of the Head and Neck.

Authors:  David J Iberri; A Dimitrios Colevas
Journal:  Oncologist       Date:  2015-10-07

3.  Activity of weekly paclitaxel-cetuximab chemotherapy in unselected patients with recurrent/metastatic head and neck squamous cell carcinoma: prognostic factors.

Authors:  I Pajares Bernad; J Martínez Trufero; L Calera Urquizu; R A Pazo Cid; A Cebollero de Miguel; M J Agustin; M Lanzuela; A Antón
Journal:  Clin Transl Oncol       Date:  2017-01-24       Impact factor: 3.340

4.  Review of cetuximab in the treatment of squamous cell carcinoma of the head and neck.

Authors:  Marco Merlano; Marcella Occelli
Journal:  Ther Clin Risk Manag       Date:  2007-10       Impact factor: 2.423
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.